In one paragraphArticle in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
18 authors.
Zoe QuandtDivision of Endocrinology and Metabolism, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-4568-4368 Karmugi BalaratnamPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Eduardo CardenasDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-3025-4058 Christina J FalconFiona and Stanley Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9143-1639 Princess Margaret Lung Group
Matthew A GubensDivision of Hematology and Oncology and UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, USA.ORCID 0000-0002-6482-1954 Scott HuntsmanDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-5440-6191 Khaleeq KhanPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Min LiDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Christine M LovlyDepartment of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, USA.ORCID 0000-0002-3641-6361 Devalben PatelPrincess Margaret Cancer Centre, Toronto, ON, Canada.
Geoffrey LiuPrincess Margaret Cancer Centre, Temerty School of Medicine, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-2603-7296 Melinda C AldrichDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-3833-8448 Adam J SchoenfeldThoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-2644-1416 Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8MVanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7MVANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7MThe Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4MThe Role of Focal Oncogene Amplifications in Lung CancerP01CA129243 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Andrea Ventura · 2007 to 2026
$31.2MPharmacogenomics of Arrhythmia TherapyU19HL065962 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RODEN, DAN M · 2010 to 2014
$17.4MDiabetes-Docs: Physician-Scientist Career Development Program (DiabDocs)K12DK133995 · NIDDK · STANFORD UNIVERSITY · PI LINDA A DIMEGLIO, David Matthew Maahs · 2022 to 2026
$16.0MInvestigational Cancer Therapeutics Training Program (ICTTP)T32CA009207 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Omar Abdel-Wahab, Alexander Drilon · 1985 to 2026
$13.7MUnderstanding and preventing HLA-associated drug reactionsP50GM115305 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2015 to 2019
$13.0MThe Genetic Epemiology of Multiple SclerosisR01NS032830 · NINDS · VANDERBILT UNIVERSITY · PI HAINES, JONATHAN L · 1995 to 2010
$8.9MEpidemiologic Architecture for Genes Linked to Environment (EAGLE)U01HG004798 · NHGRI · VANDERBILT UNIVERSITY · PI CRAWFORD, DANA C · 2008 to 2013
$8.8MNCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1 TR002243NCI NIH HHS K24 CA169004NCI NIH HHS P01 CA129243NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA068485NCI NIH HHS R01 CA227466NCI NIH HHS R01 CA251758NCI NIH HHS T32 CA009207NCI NIH HHS U01 CA253560NCI NIH HHS UG1 CA233259NCRR NIH HHS S10 RR025141NCRR NIH HHS UL1 RR024975NHGRI NIH HHS U01 HG004798NHGRI NIH HHS U01 HG006378NHLBI NIH HHS U19 HL065962NICHD NIH HHS R01 HD074711NIDDK NIH HHS K12 DK133995NIGMS NIH HHS P50 GM115305NIGMS NIH HHS RC2 GM092618NIH HHS S10 OD017985NINDS NIH HHS R01 NS032830
6 · The paper itselfAbstract
Introduction: Immune checkpoint inhibitors (ICIs) can yield remarkable clinical responses in subsets of patients with solid tumors but can also often lead to immune-related adverse events (irAEs). Predictive features of clinically severe irAEs leading to cessation of ICIs have yet to be established. Using data from 1,327 patients with lung cancer treated with ICIs between 2009 and 2022 at four academic medical centers, we evaluated the association of a germline polygenic risk score for autoimmune disease and discontinuation of ICIs due to irAEs. Methods: Using Cox proportional hazards model, we assessed the association between a polygenic risk score for autoimmune disease (PRS Results: We found an association between PRS Conclusions: We demonstrate an association between a polygenic risk score for autoimmune disease and early ICI discontinuation for irAEs, particularly among patients treated with combination ICI therapy. Our results suggest that germline genetics may be used as an adjunctive tool for risk stratification around ICI clinical decision-making in solid tumor oncology.
Identifiers
PMID38947092
PMCPMC11213033
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390